Parisian Biotech baCta Secures €7M: AI-Powered Molecular Factories Transform Industrial Ingredients
March 5, 2026, 3:37 pm
Parisian biotech baCta secured €7M Seed funding. The firm leverages AI and precision fermentation. It transforms microorganisms into molecular factories. This approach creates sustainable industrial ingredients. Their technology addresses critical supply chain issues. First target: astaxanthin. baCta aims for cost-effective, premium bio-products, replacing petrochemicals and unstable natural sourcing. The capital fuels production scale-up and platform expansion.
Parisian biotech baCta announced a significant €7 million Seed funding round. The investment propels its mission. It creates sustainable industrial ingredients. Microorganisms become programmable factories. This funding round saw leadership from LocalGlobe and Daphni. OVNI Capital also participated. Key business angels joined. They included founders of Phagos, Genomines, and Mistral AI.
Demand for industrial ingredients surges globally. Current production methods struggle. Extraction from natural sources proves expensive. It is often seasonal. Geopolitical shifts frequently disrupt supply. Climate events add severe instability. Petrochemical synthesis offers alternatives. But it carries heavy environmental burdens. It fosters deep reliance on fossil fuels. This creates supply chain fragility. baCta directly confronts these vulnerabilities. Their bio-based approach offers a resilient pathway. It decouples production from volatile external factors. This ensures consistent, ethical sourcing.
baCta offers a powerful alternative. It employs an AI-powered bioproduction platform. This platform uses precision fermentation. Microorganisms synthesize valuable organic molecules. The goal is sustainable abundance. Their approach bypasses traditional pitfalls. It delivers efficiency and resilience. The company aims to enable a future. Valuable molecules become plentiful.
The company's baCtaForge platform stands out. It merges synthetic biology advancements. Robotics integration enhances processes. Generative AI drives innovation. baCta explores genomic "dark matter." This includes long-range interactions. Regulatory pathways are analyzed. Traditional methods often overlook these critical elements. Strain design achieves unprecedented speed. The platform utilizes bio-based reinforcement learning. This cuts development costs drastically. It reduces timelines significantly. Such precision engineering promises higher yields. It ensures consistent product quality. This represents a paradigm shift in industrial biomanufacturing.
Astaxanthin represents baCta's first product. This potent antioxidant sees wide use. Human health benefits from it. Nutrition products include it. Cosmetics incorporate its properties. Animal feed relies on it. The current market faces limitations. Synthetic versions dominate. They derive from petrochemicals. Natural extraction occurs from microalgae. This process is costly.
baCta developed a proprietary yeast strain. This strain produces astaxanthin. It serves as a direct drop-in replacement. Their process aims for competitive unit economics. It rivals synthetic alternatives. Yet, it offers premium natural quality. This dual advantage positions baCta strongly. It promises a superior, sustainable supply.
The new capital fuels ambitious plans. baCta will aggressively scale astaxanthin production. Industrial processes require rigorous validation. This spans both pilot and commercial stages. A strategic partnership is paramount. A French industrial player offers crucial access. This ensures rapid scaling of production facilities. Commercialization efforts will swiftly commence. Platform expansion is also a key objective. baCtaForge's capabilities will grow. It will target additional high-value ingredients. This broadens their market reach significantly. The company aims to replace dirty, unsustainable supply chains. Biological factories offer a clean, viable path. This vision aligns perfectly with a sustainable industrial transformation. It champions environmental stewardship.
Mathieu Nohet and Marie Rouquette founded baCta. This occurred in 2024. Their vision centers on a new era. Microorganisms function as molecular factories. They produce organic molecules profitably. Commercial scale is achievable. The transition from petrochemicals is vital. baCta provides a scalable, economic path. The company previously secured pre-Seed funding. This €3.3 million round closed in October 2024. OVNI Capital led that initial investment. Now, with €7 million, baCta accelerates its impact. It paves the way for a bio-based industrial future.
Parisian biotech baCta announced a significant €7 million Seed funding round. The investment propels its mission. It creates sustainable industrial ingredients. Microorganisms become programmable factories. This funding round saw leadership from LocalGlobe and Daphni. OVNI Capital also participated. Key business angels joined. They included founders of Phagos, Genomines, and Mistral AI.
Demand for industrial ingredients surges globally. Current production methods struggle. Extraction from natural sources proves expensive. It is often seasonal. Geopolitical shifts frequently disrupt supply. Climate events add severe instability. Petrochemical synthesis offers alternatives. But it carries heavy environmental burdens. It fosters deep reliance on fossil fuels. This creates supply chain fragility. baCta directly confronts these vulnerabilities. Their bio-based approach offers a resilient pathway. It decouples production from volatile external factors. This ensures consistent, ethical sourcing.
baCta offers a powerful alternative. It employs an AI-powered bioproduction platform. This platform uses precision fermentation. Microorganisms synthesize valuable organic molecules. The goal is sustainable abundance. Their approach bypasses traditional pitfalls. It delivers efficiency and resilience. The company aims to enable a future. Valuable molecules become plentiful.
The company's baCtaForge platform stands out. It merges synthetic biology advancements. Robotics integration enhances processes. Generative AI drives innovation. baCta explores genomic "dark matter." This includes long-range interactions. Regulatory pathways are analyzed. Traditional methods often overlook these critical elements. Strain design achieves unprecedented speed. The platform utilizes bio-based reinforcement learning. This cuts development costs drastically. It reduces timelines significantly. Such precision engineering promises higher yields. It ensures consistent product quality. This represents a paradigm shift in industrial biomanufacturing.
Astaxanthin represents baCta's first product. This potent antioxidant sees wide use. Human health benefits from it. Nutrition products include it. Cosmetics incorporate its properties. Animal feed relies on it. The current market faces limitations. Synthetic versions dominate. They derive from petrochemicals. Natural extraction occurs from microalgae. This process is costly.
baCta developed a proprietary yeast strain. This strain produces astaxanthin. It serves as a direct drop-in replacement. Their process aims for competitive unit economics. It rivals synthetic alternatives. Yet, it offers premium natural quality. This dual advantage positions baCta strongly. It promises a superior, sustainable supply.
The new capital fuels ambitious plans. baCta will aggressively scale astaxanthin production. Industrial processes require rigorous validation. This spans both pilot and commercial stages. A strategic partnership is paramount. A French industrial player offers crucial access. This ensures rapid scaling of production facilities. Commercialization efforts will swiftly commence. Platform expansion is also a key objective. baCtaForge's capabilities will grow. It will target additional high-value ingredients. This broadens their market reach significantly. The company aims to replace dirty, unsustainable supply chains. Biological factories offer a clean, viable path. This vision aligns perfectly with a sustainable industrial transformation. It champions environmental stewardship.
Mathieu Nohet and Marie Rouquette founded baCta. This occurred in 2024. Their vision centers on a new era. Microorganisms function as molecular factories. They produce organic molecules profitably. Commercial scale is achievable. The transition from petrochemicals is vital. baCta provides a scalable, economic path. The company previously secured pre-Seed funding. This €3.3 million round closed in October 2024. OVNI Capital led that initial investment. Now, with €7 million, baCta accelerates its impact. It paves the way for a bio-based industrial future.